Gossamer Bio Announces 1-for-80 Reverse Stock Split
Gossamer Bio, Inc. (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension...

